Arena Pharmaceuticals Inc (ARNA)
Arena Pharmaceuticals is a biopharmaceutical company focused on delivering medicines with pharmacology and pharmacokinetics. Co.'s clinical programs include: Etrasimod, which Co. is evaluating in a Phase 3 program for ulcerative colitis, a Phase 2b/3 program for Crohn's disease, a Phase 2 program in alopecia areata, and a Phase 2b program for eosinophilic esophagitis; APD418, which is for acute heart failure; Temanogrel, which is in a Phase 2 trial for microvascular obstruction, and a Phase 2 trial for Raynaud's phenomenon secondary to systemic sclerosis; and Olorinab, which Co. is evaluating for a range of visceral pain conditions associated with gastrointestinal diseases.
|
March 28, 2024 5:59 AM Eastern
Buy (2.60 out of 4)
100th percentile
|
|